English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Yabao Pharma In-licenses China Rights to Parkinson's Drug Technology

Nov. 21, 2014

MRC Technology and Yabao Pharma, a leading Chinese pharmaceutical company, announced on November 21, 2014 an exclusive license agreement to discover, develop and commercialize innovative compounds targeting a specific kinase involved in neurodegeneration, with the aim of developing novel therapeutics for the treatment of Parkinson’s disease. Under the terms of the agreement, Yabao receives exclusive rights to discover, develop and commercialize the therapeutics in China, Taiwan and Hong Kong, whilst MRC Technology retains rights in all other markets. Financial terms have not been disclosed.